Screening of Hereditary Upper Gastrointestinal Cancer in China

NCT ID: NCT03130621

Last Updated: 2019-06-04

Basic Information

• Recruitment Status: UNKNOWN
• Total Enrollment: 500 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2017-01-31
• Study Completion Date: 2022-03-31

Brief Summary

Through exploring the specific genetic mutations in the upper gastrointestinal tract tumors with a family history and specific clinical pathological types，we establish a complete family and follow-up system，in order to improve the screening criteria of Chinese hereditary upper gastrointestinal tumors and carry on primary prevention of disease.

Conditions

Improve the Screening Criteria of Chinese Hereditary Upper Gastrointestinal Tumors

Study Design

• Observational Model Type: FAMILY_BASED
• Study Time Perspective: RETROSPECTIVE

Study Groups

Adenocarcinoma of upper digestive tract

Early-onset carcinomas ; Family History of Malignancy; Special pathological type; MSI or dMMR; Multiple primary malignant tumors;

Gene detection

Intervention Type: DIAGNOSTIC_TEST

Next-generation sequencing

Esophageal squamous cell carcinoma

Family History of Malignancy; Multiple primary malignant tumors; MSI or dMMR;

Gene detection

Intervention Type: DIAGNOSTIC_TEST

Next-generation sequencing

Interventions

Gene detection

Next-generation sequencing

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

Patients with gastric cancer, esophageal adenocarcinoma, or duodenal adenocarcinoma meet one of the following criteria:

1. age≤30;

2. age≤35，gastric cancer with special pathological types;

3. age≤50，≥one first-degree relative of a malignant tumor;

4. ≥ two first-degree／second-degree relatives of a malignant tumor，and ≥one first-degree relative;

5. have ≥two types of malignancies，and age ≤50 at the first time of diagnosis;

6. MSI or dMMR of tissue specimen;

Patients with esophageal squamous cell carcinomas meet one of the following criteria:

1. ≥ two first-degree／second-degree relatives of a malignant tumor，and ≥one first-degree relative;

2. have ≥two types of malignancies，and age ≤50 at the first time of diagnosis;

3. MSI or dMMR of tissue specimen;

• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Peking University

OTHER

Sponsor Role: lead

Responsible Party

Shen Lin

Chief physician

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

Beijing Cancer Hospital

Beijing, Beijing Municipality, China

Site Status: RECRUITING

Countries

China

Facility Contacts

Shen Lin, Professor

Role: primary

Linshenpku@163.com

010-88196561

Other Identifiers

CGOG1012

Identifier Type: -

Identifier Source: org_study_id